Evidence map›Paper›PMID 32144874›Full record

ArticleJournal of the International AIDS Society2020

The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.

Jennifer Velloza, Nomhle Khoza, Fiona Scorgie, Miria Chitukuta, Prisca Mutero, Kudzai Mutiti, Nomvuyo Mangxilana, Lumka Nobula, Michelle A Bulterys, Millicent Atujuna and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 3 syntheses or guidelines pooled it, 227 citations in OpenAlex.

  1. Pooled it
  2. Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 3 countries.

Jennifer VellozaUniversity of Washington, Seattle, WA, USA.ORCID 0000-0001-7242-7415
Nomhle KhozaWits Reproductive Health & HIV Institute (Wits RHI), Johannesburg, South Africa.
Fiona ScorgieWits Reproductive Health & HIV Institute (Wits RHI), Johannesburg, South Africa.
Miria ChitukutaClinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Prisca MuteroClinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Kudzai MutitiClinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Nomvuyo MangxilanaDesmond Tutu HIV Foundation, Cape Town, South Africa.
Lumka NobulaDesmond Tutu HIV Foundation, Cape Town, South Africa.
Michelle A BulterysUniversity of Washington, Seattle, WA, USA.
Millicent AtujunaDesmond Tutu HIV Foundation, Cape Town, South Africa.
Sybil HosekStroger H. Hospital of Cook County, Chicago, IL, USA.
Renee HeffronUniversity of Washington, Seattle, WA, USA.ORCID 0000-0001-6039-0352
Linda-Gail BekkerFaculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Nyaradzo MgodiClinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Mike ChirenjeClinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Connie CelumUniversity of Washington, Seattle, WA, USA.ORCID 0000-0002-8813-3419
Sinead Delany-MoretlweFaculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
HPTN 082 study group
University of Zimbabwe · ZWUniversity of Washington · USDesmond Tutu HIV Foundation · ZAPerinatal HIV Research Unit · ZAJohn H. Stroger, Jr. Hospital of Cook County · USUniversity of Cape Town · ZAUniversity of the Witwatersrand · ZA

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
HIV Prevention trials Network (HPTN) Coordinating and Operations CenterU01AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI VERMUND, STEN H. · 2006 to 2010
$72.7M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Leadership for HIV/AIDS Clinical Trials Networks; HIV Prevention Trials NetworkU01AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DONNELL, DEBORAH J · 2006 to 2010
$28.8M
Units for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2M
VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
HIV Prevention Trials Network: Network LaboratoryU01AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2006 to 2010
$16.5M
NIAID NIH HHS P30 AI027757NIAID NIH HHS T32 AI007140NIAID NIH HHS U01 AI068613NIAID NIH HHS U01 AI068617NIAID NIH HHS U01 AI068619NIAID NIH HHS U01 AI069436NIAID NIH HHS U01 AI069463NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069463NIMH NIH HHS F31 MH113420
6 · The paper itself

Abstract

introductionStigma and disclosure concerns have been key barriers to oral pre-exposure prophylaxis (PrEP) adherence for African adolescent girls and young women (AGYW) in efficacy trials. We aimed to understand the impact of these factors among African AGYW in an open-label PrEP study.

methodsHPTN 082 was an open-label PrEP study among AGYW (ages 16 to 24) in Harare, Zimbabwe, and Cape Town and Johannesburg, South Africa from 2016 to 2018. Women starting PrEP were randomized to standard adherence support (counselling, two-way SMS, monthly adherence clubs) or standard support plus drug-level feedback. Serial in-depth interviews were conducted among 67 AGYW after 13-week and 26-week study visits to explore experiences of stigma, disclosure and PrEP adherence. We analysed data by coding transcripts and memo-writing and diagramming to summarize themes.

resultsAGYW described stigma related to sexual activity (e.g. "people say I'm a prostitute") and being perceived to be living with HIV because of taking antiretrovirals (e.g. "my husband's friends say I'm HIV infected"). Participants who anticipated stigma were reluctant to disclose PrEP use and reported adherence challenges. Disclosure also resulted in stigmatizing experiences. Across all sites, negative descriptions of stigma and disclosure challenges were more common in the first interview. In the second interview, participants often described disclosure as an "empowering" way to combat community-level PrEP stigma; many said that they proactively discussed PrEP in their communities (e.g. became a "community PrEP ambassador"), which improved their ability to take PrEP and encourage others to use PrEP. These empowering disclosure experiences were facilitated by ongoing HPTN 082 study activities (e.g. counselling sessions, adherence clubs) in which they could discuss PrEP-related stigma, disclosure and PrEP adherence issues.

conclusionsStigma and disclosure challenges were initial concerns for African AGYW newly initiating PrEP but many were empowered to disclose PrEP use over their first six months of PrEP use, which helped them cope with stigma and feel more able to take PrEP regularly. PrEP programmes can foster disclosure through community and clinic-based discussion, adherence clubs and activities normalizing sexual behaviour and PrEP use, which can reduce stigma and improve PrEP adherence and thus effectiveness.

Indexed as

DisclosureMedication AdherencePre-Exposure ProphylaxisSocial StigmaAdultAnti-HIV AgentsCounselingFemaleHIV InfectionsHumansQualitative ResearchSexual BehaviorSouth AfricaYoung AdultZimbabweAnti-HIV AgentsAfricadisclosureHIVpre-exposure prophylaxisStigmawomen

Identifiers

PMID32144874
PMCPMC7060297
OpenAlexW3010508615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.